Entacapone: adjunctive use in patients with advanced Parkinson's disease

McAuley L

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To summarise the available evidence on entacapone (trade name Comtan(R)) for adjunctive use in patients with advanced Parkinson's disease.

Authors' conclusions
Based on current evidence, entacapone provides clinically important improvement in function for patients with Parkinson's disease suffering from symptoms of motor fluctuations. Long-term efficacy data beyond 6-month follow-up are not currently available.

Entacapone was generally well tolerated in clinical trials. Most adverse events are mild and do not lead to discontinuation of treatment.

The impact of entacapone on disease progression is unclear. There is no evidence to consider adjunctive therapy with entacapone at the onset of levodopa therapy.

The ability of entacapone to delay the onset of motor fluctuations in PD patients not currently experiencing these fluctuations, requires further study.

Project page URL
https://www.ccohta.ca/research/index.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Costs and Cost Analysis; Parkinson Disease /drug therapy

Language Published
English, French

Country of organisation
Canada

Address for correspondence
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392; Email: jills@ccohta.ca.

AccessionNumber
32001000040